Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-02T19:40:55.520Z.
Calculation as of: 2026-10-02T19:40:55.520Z.
Quote observation: 2026-10-02T19:40:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a42e17afc1a1b5c0c05c4bcc318afc1e85bdb01f5d7a677422ba224d703768eb
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | $2.14B | N/A | N/A | N/A | N/A |
| Beam Therapeutics Inc. (BEAM)vs › | $2.51B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | N/A | 6.61 | 5.90 | 4.86 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | N/A | 4.41 | 4.41 | 4.41 |
| NRC Health (NRC)vs › | $459.30M | N/A | 6.07 | 3.14 | 2.42 |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute